

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2016 UK

DISPATCHED ON 26TH JULY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A30; B8, B60; Cw7, Cw10; DR4, DR17; DQ2, DQ8

			Summary of Results								
			PBL/T-Cells				B-Cells				
Total tested			20	19	21	21	19	20	19	19	
Positive			2	18	0	14	19	20	7	17	
Negative			18	1	21	7	0	0	12	2	
NT/Equivocal			1	2	0	0	1	0	1	1	
% Positive			10.0%	94.7%	0.0%	66.7%	100.0%	100.0%	36.8%	89.5%	
% Negative			90.0%	5.3%	100.0%	33.3%	0.0%	0.0%	63.2%	10.5%	
Consensus			Negative	Positive	Negative	Not Assessed	Positive	Positive	Not Assessed	Positive	
HLA Antibody Specificity (Defined By CDC)			A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1	A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1	
			Without DTT				Without DTT				
Lab No.	PBL/T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
9	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Results reported on separated T and B cells NIH scores
11	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Positive	Positive	
12	YES	YES	Negative	Equivocal	Negative	Positive	Positive	Positive	Positive	Positive	
14	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Positive	Positive	
15	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
20	YES	YES	Negative	Negative	Negative	Positive	Positive	Positive	Negative	Positive	
23	YES	YES	Equivocal	Positive	Negative	Positive	Equivocal	Positive	Negative	Positive	
24	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Positive	Positive	
25	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Equivocal	
28	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
34	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
35	YES	NO	Negative	Positive	Negative	Positive					
38	YES	YES	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Positive	
39	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Positive	Positive	
41	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Positive	
42	YES	YES	Positive	Positive	Negative	Positive	Positive	Positive	Positive	Positive	
45	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Positive	
51	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
54	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Positive	Positive	
58	YES	YES	Negative	Equivocal	Negative	Positive	Positive	Positive	Equivocal	Positive	
62	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2016 UK

DISPATCHED ON 26TH JULY 2016

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	4	0	0	6	6	0	0		95	90
11	-	4	-	-	8	8	4	6	90	85	85
12	-	-	-	6	8	8	2	8		95	90
14	0	2	0	4	8	8	4	8		90	90
15	-	1	-	1	8	8	-	4		95	80
20	0-10%	0-10%	0-10%	20-40%	90-100%	90-100%	0-10%	90-100%		95	95
23	-	6	1	4	-	8	1	4		90	80
24	10	30	10	30	100	100	40	80	90	90	90
25	1	6	1	1	8	8	1	2		99	99
28	1	4	1	4	8	8	1	8		90	90
34	1	2	1	6	8	8	1	8		99	95
35	1	8	1	4					90	65	
38	4	6	1	1	8	8	1	6	90	85	85
39	-	4	-	2	8	8	6	8		90	90
41	10%	45%	3%	25%	95%	98%	10%	25%		95	95
42	10-20%	60-80%	<10%	20-40%	80-100%	80-100%	~10%	40-60%	95		95
45	1	8	1	1	8	8	1	8		90	90
51	0	8	0	4	8	8	0	8	95	95	90
54	5%	90%	5%	75%	90%	90%	40%	90%		95	95
58	5%	-	5%	50%	100%	100%	-	100%		95	95
62	1	4	1	2	8	8	1	1		95	70

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2016 UK

DISPATCHED ON 26TH JULY 2016

Lab No.	Summary of Results															
	PBL				PBL Without DTT				T-Cells				T-Cells Without DTT			
	Without DTT				Serum 1	Serum 2	Serum 3	Serum 4	Without DTT				Serum 1	Serum 2	Serum 3	Serum 4
	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength
9	Positive	Positive	Negative	Negative	2	4	0	0	Negative	Positive	Negative	Negative	0	4	0	0
15	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Positive	-	1	-	1
20	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Positive	0-10%	0-10%	0-10%	20-40%
38	Positive	Positive	Negative	Negative	4	6	1	1	Positive	Positive	Negative	Negative	4	6	1	1
41	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Negative	10%	45%	3%	25%
42	Positive	Positive	Negative	Positive	10-20%	60-80%	<10%	20-40%	NT	NT	NT	NT	NT	NT	NT	NT
51	Negative	Positive	Negative	Positive	0	8	0	4	Negative	Positive	Negative	Positive	0	6	0	4
54	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Positive	5%	90%	5%	75%

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2016 UK

DISPATCHED ON 26TH JULY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A30; B8, B60; Cw7, Cw10; DR4, DR17; DQ2, DQ8

			Summary of Results								
			PBL/T-Cells				B-Cells				
Total tested			17	15	17	17	17	17	16	17	
Positive			2	11	0	0	17	17	4	2	
Negative			15	4	17	17	0	0	12	15	
NT/Equivocal			1	3	1	1	0	0	1	0	
% Positive			11.8%	73.3%	0.0%	0.0%	100.0%	100.0%	25.0%	11.8%	
% Negative			88.2%	26.7%	100.0%	100.0%	0.0%	0.0%	75.0%	88.2%	
Consensus			Negative	Not Assessed	Negative	Negative	Positive	Positive	Negative	Negative	
HLA Antibody Specificity (Defined By CDC)			A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1	A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1	
			With DTT				With DTT				
Lab No.	PBL/T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
9	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Results reported on separated T and B cells NIH scores
11	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Positive	Positive	
12	YES	YES	Negative	Equivocal	Negative	Negative	Positive	Positive	Positive	Negative	
14	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
15	YES	YES	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
20	YES	YES	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
24	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
25	YES	YES	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Serum 3 and 4 B cell negative with DTT, results above background but not high enough to call positive. Would want to have Flow Crossmatch and Antibody information for these samples. PBL/T cells Serum 1-4 technically unsatisfactory
28	YES	YES	NT	NT	NT	NT	Positive	Positive	Negative	Negative	
34	YES	YES	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
35	YES	NO	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
38	YES	YES	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
39	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Positive	Positive	
41	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
42	YES	YES	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Negative	
45	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
51	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
58	YES	YES	Negative	Equivocal	Negative	Negative	Positive	Positive	Equivocal	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2016 UK

DISPATCHED ON 26TH JULY 2016

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	4	0	0	6	6	0	0		95	90
11	-	4	-	-	8	8	2	4	90	85	85
12	-	-	-	-	8	8	2	-		95	90
14	0	2	0	0	8	8	0	7		90	90
15	-	-	-	-	8	8	-	-		95	80
20	0-10%	0-10%	0-10%	0-10%	70-80%	90-100%	0-10%	0-10%		95	95
24	10	30	10	10	100	100	20	20	90	90	90
25	1	1	1	1	6	8	1	1		99	99
28	NT	NT	NT	NT	8	8	1	1		90	90
34	1	1	1	1	8	8	1	1		99	95
35	1	8	1	1					90	65	
38	4	4	1	1	8	8	1	1	90	85	85
39	-	2	-	-	8	8	6	6		90	90
41	10%	85%	7%	10%	95%	98%	18%	18%		95	95
42	10-20%	60-80%	<10%	<10%	80-100%	80-100%	~10%	<10%	95		95
45	1	8	1	1	8	8	1	1		90	90
51	0	8	00-Jan	00-Jan	8	8	0	0	95	95	90
58	5%	-	5%	5%	100%	100%	-	5%		95	95

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2016 UK

DISPATCHED ON 26TH JULY 2016

Lab No.	Summary of Results															
	PBL				PBL With DTT				T-Cells				T-Cells With DTT			
	With DTT				Serum 1	Serum 2	Serum 3	Serum 4	With DTT				Serum 1	Serum 2	Serum 3	Serum 4
	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength
9	Positive	Positive	Negative	Negative	2	4	0	0	Negative	Positive	Negative	Negative	0	4	0	0
15	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	-	-	-	-
20	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	0-10%	0-10%	0-10%	0-10%
38	Positive	Positive	Negative	Negative	4	4	1	1	Positive	Positive	Negative	Negative	4	4	1	1
41	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Negative	10%	85%	7%	10%
42	Positive	Positive	Negative	Negative	10-20%	60-80%	<10%	<10%	NT	NT	NT	NT	NT	NT	NT	NT
51	Negative	Positive	Negative	Negative	0	8	0	0	Negative	Positive	Negative	Negative	0	4	0	0
54	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT